EFFICIENCY OF ANTI-INFLAMMATORY THERAPY IN PATIENTS WITH ANKYLOSING SPONDYLITIS ACCORDING TO THE RESULTS OF A PROSPECTIVE FOLLOW-UP STUDY
In accordance with the Ankylosing Spondylitis Assessments (ASAS) International Working Group guidelines, tumor necrosis factor-α inhibitors are recommended in patients with ankylosing spondylitis (AS) refractory to at least two nonsteroidal anti-inflammatory drugs (NSAIDs) and in those with the...
Main Authors: | T. A. Raskina, O. S. Malyshenko, O. A. Pirogova, M. A. Volykova |
---|---|
Format: | Article |
Language: | Russian |
Published: |
IMA PRESS LLC
2016-09-01
|
Series: | Научно-практическая ревматология |
Subjects: | |
Online Access: | https://rsp.mediar-press.net/rsp/article/view/2253 |
Similar Items
-
Choice of a nonsteroidal anti-inflammatory drug in ankylosing spondylitis
by: Rimma Mikhailovna Balabanova, et al.
Published: (2014-12-01) -
Nonsteroidal anti-inflammatory drugs: a basis for the treatment of ankylosing spondylitis
by: A A Godzenko
Published: (2011-12-01) -
Comparative efficacy of infliximab and adalimumab in patients with ankylosing spondylitis
by: Tatyana Valentinovna Mezenova, et al.
Published: (2012-04-01) -
Prospects for the use of celecoxib in patients with ankylosing spondylitis: impact on retarding disease progression
by: Yulia Leonidovna Korsakova
Published: (2012-09-01) -
Musculoskeletal losses in patients with ankylosing spondylitis
by: T. A. Raskina, et al.
Published: (2019-10-01)